Equity Overview
Price & Market Data
Price: $7.60
Daily Change: -$0.42 / 5.53%
Range: $7.56 - $8.12
Market Cap: $121,577,200
Volume: 34,142
Performance Metrics
1 Week: -2.94%
1 Month: 40.48%
3 Months: -1.94%
6 Months: 35.96%
1 Year: -6.75%
YTD: 49.02%
Company Details
Employees: 32
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.